Colorectal cancer (CRC) treatment is largely determined by tumor stage. Despite improvements made in the treatment of various types of metastatic disease, staging has not been refined. The role of tumor deposits (TDs) in staging remains debated. We have assessed the relation of TDs with metastatic pattern to evaluate whether TDs might add significant new information to staging.
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Colorectal cancer (CRC) treatment is largely determined by tumor stage. Despite improvements made in the treatment of various types of metastatic disease, staging has not been refined. The role of tumor deposits (TDs) in staging remains debated. We have assessed the relation of TDs with metastatic pattern to evaluate whether TDs might add significant new information to staging.
Methods
We performed a systematic literature search that was focused on the role of TDs in CRC. Studies with neoadjuvant-treated patients were excluded. Data on stage, histologic factors, and outcome were extracted. Data from four large cohorts were analyzed for the relevance of the presence of TDs, lymph node metastases (LNMs), and extramural vascular invasion (EMVI) on the pattern of metastases and outcomes.
Results
Of 10,106 included patients with CRC, 22% presented with TDs. TDs are invariably associated with poor outcome. Presence of TDs was associated with presence of LNMs and EMVI. In a pairwise comparison, effects of TD were stronger than those of both LNMs and EMVI. In the logistic regression model, TDs in combination with LNMs is the strongest predictor for liver (odds ratio [OR], 5.5), lung (OR, 4.3) and peritoneal metastases (OR, 7.0). Presence of EMVI adds information for liver and lung metastases, but not for peritoneal metastases.
Conclusion
We have shown that TDs are not equal to LNMs or EMVI with respect to biology and outcome. We lose valuable prognostic information by allocating TDs into nodal category N1c and only considering TDs in the absence of LNMs. Therefore, we propose that the number of TDs should be added to the number of LNMs to derive a final N stage.
INTRODUCTION
Staging of cancer is one of the cornerstones of cancer treatment. The TNM staging system is an anatomically based classification that is applied worldwide for many tumor types. Originally, this system was used to determine prognostic outcomes and to enable the international comparison of different cohorts. With increasing treatment possibilities, tumor stage has become one of the main selection criteria for (adjuvant) therapy. In colorectal cancer (CRC), stage III patients are generally treated with systemic adjuvant therapy, as are patients with high-risk stage II disease. 1, 2 However, for many patients with metastatic disease, cytotoxic therapy is no longer their only treatment option and more widespread multimodality treatment with curative intent has become possible. Patients with oligometastases in liver or lung can undergo curative treatment in ever increasing numbers, 3, 4 and patients with peritoneal disease can undergo cytoreduction with hyperthermic intraperitoneal chemotherapy treatment. 5 Clinical trials that will investigate treatment with adjuvant hyperthermic intraperitoneal chemotherapy in high-risk patients are currently recruiting. 6 Therefore, we need more detailed staging systems that enable a better estimation for recurrence risk at different sites to guide new treatment choices.
In recent editions of the TNM staging system, inclusion of tumor deposits (TDs) within nodal staging has given rise to worldwide discussions. [7] [8] [9] [10] [11] [12] Other important prognostic features, such as extramural vascular invasion (EMVI), are acknowledged but not included in staging. One may wonder whether we lose useful information by ignoring the former and placing TDs with different etiologies into the nodal category, N1c, only in the absence of lymph node metastases (LNMs). If TDs are equal to LNMs, both in prognostic and biologic sense, this would simplify the staging systems as they can be placed in the N category without loss of information; however, if TDs add information to staging, either alone or taking into account their etiology, we should apply specific substaging.
We assessed the prognostic impact of TDs by performing a systematic review of existing data, investigated the association of TDs with other histologic prognostic factors, and determined whether TD status influenced the metastatic pattern in CRC. On the basis of the results, we propose revisions to be considered for the modern anatomic staging of CRC.
METHODS

Strategy for Search of Articles and Selection Criteria
A comprehensive literature search for published studies was performed by using Embase and Medline databases (OvidSP software; Ovid Technologies, New York, NY) from inception to July 29, 2015 using the following keywords: "tumor deposits" or "microfoci" or "non-nodal" or "nodal independent" or "neoplastic foci" or "tumor aggregate" or "discontinuous" or "extranodal" or "staging" in combination with "Colorectal Neoplasms"[Mesh] "Cecal Neoplasms" [Mesh] or "colorectal" or "colon" or "rectum" or "rectal" and "cancer" or "carcinoma" or "tumor", limited by "Survival Analysis" [Mesh] . Additional searches were performed by manual cross-referencing.
Only original studies that were published in English with at least 100 patients were selected. In case of overlapping patient data, results of the largest study or of the study with longest follow-up were included in this meta-analysis. Studies in which histology was not reviewed for whole cohorts were excluded, as reporting on TDs without histologic review is unreliable and incomplete. Studies that included patients who were treated with neoadjuvant therapy were excluded. Test and validation cohorts that have been described in the individual studies are separately analyzed.
Data Extraction
For each study, the number of patients in both the TD-positive and TD-negative groups were obtained. Data on tumor stage, histologic factors, 5-year disease-free survival (DFS), 5-year disease-specific survival (DSS), and 5-year overall survival (OS) were extracted from all studies. Data were entered in SPSS for Windows version 22 (SPSS, Chicago, IL) and Review Manager (version 5.3; Cochrane Tech, London, United Kingdom). Data were retrieved by two independent investigators (I.D.N. and N.K.).
Quality Assessment and Risk of Bias
A scale to assess the quality of study reporting was developed on the basis of the REMARK guidelines and focused on TDs (Appendix Table A1 , online only).
13,14 All studies were subjected to quality assessment; studies that were only used for correlation of TDs with other factors were subjected to quality assessment in which outcome-specific items were left out. The association between the quality of reporting and the hazard ratio (HR) was analyzed with scatter plots and nonparametric correlation testing. Publication bias was assessed by symmetry in funnel plots.
Cohort Description
Data from four cohorts was further explored to determine the association between TDs and metastatic patterns. These cohorts have been extensively described elsewhere. 9, 15 In brief, the first cohort is the test cohort from the Japanese Society for Cancer of the Colon and Rectum,  which included 1,716 patients with stage I to III CRC who underwent  curative surgery between 1994 and 1998, with an average follow-up of  93 months.  15 The validation cohort from the Japanese Society for Cancer  of the Colon and Rectum included 2,242 patients with stage I to III CRC  who underwent curative surgery between 1999 and 2003, with an average  follow-up of 68 months. 15 The UK cohort consists of 455 patients with stage I to IV CRC who were included in the Medical Research Council CLASICC trial between July 1996 and July 2002, with an average follow-up of 63 months. 9 The Swedish cohort represents a consecutive case series from Falu Lasarett of 505 patients with stage I to IV CRC who underwent surgery between 1998 and 2000, with an average follow-up of 63 months.
9
Histology from all cases was reviewed with special attention for TDs, as has been described before.
9,15
Statistical Analysis
A meta-analysis was performed with all available studies on correlation in terms of risk ratios (RRs) with 95% CI. Data of univariable and multivariable analyses were entered in terms of HR with 95% CI. If no HR was reported, it was calculated from the published data, 16 but only in studies with data on minimum and maximum follow-up times. A random effects model with inverse variance weighting of studies was used. In this model, each study was given a weight that was equal to the inverse of the variance of the effect estimate and served to minimize the variance of the combined effect. Forest plots were used to demonstrate consistency of results. For effect size, Z-statistic was used (standardized mean difference). Heterogeneity was assessed by using a x 2 test for heterogeneity with a P value of , .10 to show the presence of significant heterogeneity. Furthermore, we applied I 2 statistic-percentage of variation across studies that is a result of heterogeneity rather than chance-in combination with Tau-squared-estimate of between-study variance in a random effect meta-analysis. In case of heterogeneity, subanalyses for sample size, timeframe, and TNM stage were performed to identify the potential source of the heterogeneity. Logistic regression analysis was used to investigate the multivariable relationship of pathologic factors that predicted liver, lung, and peritoneal metastases in the four cohorts. In logistic regression analyses, the reference group used was the negative/negative group, that is, N0/TD negative. In the model, all first-order interactions were included, adjusting for cohort, LNMs, TDs, EMVI, and the combination of LNM*TD, LNM*EMVI, and TD*EMVI. The model was simplified by leaving out nonstatistical interactions with a P value of . .10. Results were reported as odds ratios (ORs) with 95% CI. A P value # .05 was considered statistically significant. Hosmer and Lemeshow test for goodness of fit was used to evaluate logistic regression models. We applied the Holm method for stepdown Bonferroni correction of multiple testing for each factor.
RESULTS
Search Results
A total of 574 studies were retrieved by the Medline database search, and 605 we found by using Embase. Duplicates were excluded (n 5 283). A further 862 studies were excluded because they did not meet general inclusion criteria (Fig 1) . We added two additional papers that fulfilled eligibility criteria. 17, 18 The remaining 36 papers concerned TDs in CRC. We excluded six studies because of insufficient patient numbers, 19-24 one gave insufficient data for analysis, 25 two studies did not perform histologic revision of all historic cases, 18,26 and seven studies had overlapping data.
12,27-32
Three studies included neoadjuvant-treated patients.
33-35
The remaining 17 studies, which comprised 10,106 patients, were included in the meta-analysis. The main characteristics of the studies are listed in Table 1 .
Quality of the Reporting of the Included Studies
Studies were subjected to quality assessment (Appendix Table A1 ). Thirteen studies were used for meta-analysis with outcome, 15,17,36,37,41-45,47-49 of which nine studies could also be used for correlation of TDs with other factors.
15,17,41-44,47-49 Two additional studies had no data on outcome and were only used for correlation of TDs with other factors.
9,46 Moreover, three studies that were identified in our systematic review provided insufficient data for meta-analysis. [38] [39] [40] The mean percentage of items that were reported in studies with outcome data was 66.6% (range, 39% to 84%). The mean percentage of items reported in studies with data for correlation was 71.6% (range, 50% to 82%).
Frequency and Impact of TDs
The average frequency of TDs for all studies was 22.0% (range, 4.9% to 41.8%).
Data on the impact of TDs on DFS in univariable analysis was available from five studies, which included, in total, 1,246 patients. In the presence of TDs, DFS was significantly decreased (HR, 2.2; 95% CI, 1.6 to 3.0; Fig 2A) . Considerable heterogeneity was observed among studies (I 2 5 78%). With respect to the quality assessment of studies, the percentage of items reported ranged from 50% to 84%, and this did not correlate with the magnitude of Puppa (2007) Lin (2015) Goldstein ( HR IV (random 95% CI)
Shimada (2010) Nagayoshi (2014) Lin (2015) Goldstein (2000) von Winterfeld (2014 HR (Spearman r 5 0.56; P 5 .35). Multivariable DFS analysis was available in five studies that comprised 1,536 patients and that confirmed decreased DFS in the presence of TDs (HR, 2.0; 95% CI, 1.4 to 2.8; Fig 2B) . Substantial heterogeneity was observed among studies (I 2 5 66%). With respect to the quality assessment of the studies, the percentage of items reported ranged from 65% to 84%, and this did not correlate with the magnitude of HR (Spearman r 5 0.82; P 5 .13).
The effect of TDs on DSS in univariable analysis was determined in five cohorts that comprised 4,446 patients (Fig 2C) and that confirmed decreased DSS in the presence of TDs (HR, 3.3; 95% CI, 2.2 to 4.7). Considerable heterogeneity was observed among studies (I 2 5 83%). With respect to the quality assessment of the studies, the percentage of items reported ranged from 50% to 79%, and this did not correlate with the magnitude of HR (Spearman r 5 20.16; P 5 .78). Multivariable DSS analysis was available in four studies that comprised 1,185 patients and that confirmed decreased DSS in the presence of TDs (HR, 1.7; 95% CI, 1.4 to 2.1; Fig 2D) . No heterogeneity was observed among studies (I 2 5 0%). The percentage of items reported ranged from 50% to 79%, and this quality indicator did not correlate with the magnitude of HR (Spearman r 5 20.80; P 5 .33).
The impact of TDs on OS was available from three univariable and five multivariable cohorts with 814 and 1,699 patients, respectively (Figs 2E and 2F). OS was decreased in the presence of TDs (univariable HR, 2.9; 95% CI, 2.2 to 3.8; and multivariable HR, 2.2; 95% CI, 1.7 to 2.8). No heterogeneity was observed in the univariable analysis (I 2 5 0%), nor the multivariable analysis (I 2 5 0%). For univariable studies, the percentage of items reported ranged from 56% to 84%, which did not correlate with the magnitude of HR (Spearman r 5 20.50; P 5 1.00). For multivariable studies, the percentage ranged between 65% and 84%, which did not correlate with the magnitude of HR (Spearman r 5 0.60; P 5 .35).
None of the analyses showed evidence of publication bias (Appendix Fig A1, online only) . Observed heterogeneity in DFS and DSS analyses could not be explained by differences in sample size, timeframe, and TNM stage. Despite the observed heterogeneity, the direction of the effect in the forest plots is rather consistent. HR as a result of TD is smaller in the multivariable models, as would be expected because additional variance is accounted for; however, inclusion of these additional covariates does not diminish the significance of the HR as a result of TD. Additional information about the covariates that were included in the multivariable analyses are listed in Appendix Table A2 (online only).
Subdivisions of TD: Does it Matter?
The size of TDs influences prognosis: larger TDs (. 12 mm in diameter) have a significantly poorer DSS compared with small TD (# 3 mm; HR, 2.5 and 3.2, respectively). 15 Between 3 mm and 12 mm, there was a nonsignificant increase in HR as a function of TD size. In another study 44 small TDs, defined as , 2 mm, showed a good DFS compared with that of larger TDs.
The contour of TDs can be described as smooth or irregular. Two studies 11,44 of 214 and 3,958 patients demonstrated a trend toward poorer outcomes in the irregular groups; however, no direct comparison was performed.
Increasing numbers of TDs are associated with poor outcome. In the absence of LNMs, four or more TDs were associated with a significantly shorter survival in a small group of patients (n 5 17; 16.5 months v 32.5 months; P 5 .025). 40 Goldstein and Turner 41 showed that, regardless of nodal status, the 5-year survival of patients with three or more TDs was significantly worse compared with patients with only one or two TDs (2% v 24%; P , .01).
Associations Between TD and Histologic Risk Factors
The relationship between nodal status and the presence of TD was studied in 13 cohorts with a total of 7,583 patients (Appendix Fig A2A, online only) . TDs were present in 8.7% of patients without LNMs compared with 41.6% of patients with LNMs. There were six cohorts in which the number of involved lymph nodes was studied (Appendix Fig A2B) ; there was a significant increase in TDs with increasing N stage in all studies (P 5 .002, Friedman test). RR for TDs in the presence of LNMs was 4.2 (95% CI, 3.2 to 5.6; Appendix Fig A2A) .
The relationship between TD and EMVI (as determined by examination of hematoxylin-eosin-stained slides) was studied in nine cohorts with a total number of 2,805 patients (Appendix Fig  A2C) . TDs were present in 20.9% of patients without EMVI compared with 31.6% of patients with EMVI. RR for TDs in the presence of EMVI was 2.6 (95% CI, 1.8 to 3.7; Appendix Fig  A2C) .
Comparison of LNMs, TDs, and EMVI
Two studies investigated the prognostic power of TDs in combination with LNMs.
44,46 Whereas absence and presence of both TDs and LNMs was associated with the best and worst outcomes, respectively, both studies suggest that the presence of only TDs is associated with a worse outcome than the presence of only LNMs.
To establish the value of TDs, LNMs, and EMVI in modern staging, we analyzed original data from four large cohorts of studies 9,15 that were selected in this systematic review in correlation with metastatic patterns, including both synchronous and metachronous metastases. Three different metastatic patterns were distinguished: liver metastases, lung metastases, and peritoneal metastases. In the four cohorts, which had a total of 4,918 patients, there were 397 liver metastases, 268 lung metastases, and 92 peritoneal metastases. The distribution of metastases was different between the cohorts, with higher percentages of liver and peritoneal metastases in the Sweden cohort (Fig 3A) .
For RR at different metastatic locations (Fig 3B) , the effect of LNMs was similar to that of TDs; however, the combination of TDs and LNMs was associated with a significantly higher risk of liver metastases than LNMs alone. When TDs and EMVI were compared (Fig 3C) , it was clear that the presence of TDs significantly increased RR of liver metastases (RR, 3.6; 95% CI, 2.6 to 5.0 v RR, 1.7; 95% CI, 1.3 to 2.3). RR of TDs was not different from the RR of TD and EMVI combined. For lung metastases, the combination of TDs and EMVI significantly increased RR compared with EMVI alone. When the impact of EMVI in combination with LNMs was compared, it was clear that addition of LNMs caused a higher RR for both lung and liver metastases (Fig 3D) .
We subsequently evaluated the different factors by using a logistic regression model (Table 2) . For liver metastases, TDs, LNMs, and EMVI were significant, with ORs of 3.6, 2.6, and 1.4, respectively. For lung metastases, the effects of TDs, LNMs, and EMVI were comparable (OR, 2.9, 2.5, and 2.0, respectively). For the development of peritoneal metastases, only TDs and LNMs contributed significantly (OR, 6.4 and 3.2, respectively), but not EMVI. Combination of TDs and LNMs did not increase the risk of peritoneal metastases compared with TDs alone.
DISCUSSION
In the current systematic review, we identified 17 large-scale studies that investigated the role of TDs in CRC. In a collection of 10,106 patients with CRC patients, the incidence of TDs was 22%, which illustrates its potential value. The presence of TDs was invariably associated with a poorer outcome as illustrated by decreased DFS (HR, 1.7 to 2.0), DSS (HR, 1.7 to 3.9), and OS (HR, 2.2 to 2.9). Some unexplained heterogeneity was present in DFS and DSS analyses; however, OS analyses did not show heterogeneity. Recent editions of TNM have acknowledged the importance of TD by incorporating it in nodal staging. In the 5th edition of TNM, 51 the size of TD was considered important, but this was replaced by contour in the 6th edition 52 and by local interpretation in the 7th edition. 53 Despite the clinical impact of these definitions, limited data are available to study both size and contour. Two studies 15, 44 have confirmed that size matters by demonstrating that larger TDs are associated with worse prognosis. Data on the impact of contour is less convincing.
The correlation between TDs and other types of regional spread might be part of the explanation of the poor prognosis. TDs occur more frequently in cases with perineural invasion 21,41,43 and lymphatic invasion. 17,42-44,46,49 We summarized the most relevant correlations and demonstrated increased TDs in patients with LNMs and EMVI; however, data from multivariable studies still demonstrate an independent prognostic effect of TDs.
It is important to realize that TDs are not LNMs: the origin of TDs is diverse. By serial sectioning in a series of 30 irregular TDs, 37 almost 40% showed a combined perineural, perivascular, and intravascular origin. A perineural origin was present in 77% of cases and an intravascular origin in 83% of cases. A similar setup with 69 TDs 54 showed similar diversity. Presence of vessels and nerves in the majority of TDs explains the worse prognosis of patients with TDs compared with that of patients with LNMs alone. Tumor access to more than one anatomic highway to metastatic locations creates more extensive tumor spread; therefore, we decided to evaluate the metastatic patterns that occur in the presence of TDs. The early study of Goldstein and Turner 37 suggested a significant impact of TDs in the development of intra-abdominal metastases. In their cohort, only 12% of patients without TDs developed peritoneal metastases compared with 44% of patients with TDs. In the current study, we examined original data from four different patient cohorts and the impact of TDs on the pattern of metastases. Presence of TDs and LNMs more than doubled the RR (5.3 v 2.5) for liver metastases compared with LNM alone. Similar trends are observed for other metastatic patterns. A first explanation would be that TDs indeed reflect EMVI and thus explain the high risk of liver metastases 55 ; however, when we compared TDs and EMVI, the difference was even more pronounced. Whether there is an unequivocal alternative biologic explanation 56 remains to be investigated. From these results, it is clear that TDs do not equate to LNMs, nor recognizable EMVI, both in a prognostic and in a biologic sense. This study shows that by allocating all TDs into a nodal category, pN1c, and subsequently ignoring them in the presence of LNMs, valuable prognostic information is lost. The same argument can be made for EMVI; we also lose potential information on the likely sites for recurrence.
This study confirms that sufficient consistent evidence exists to now justify TD assessment in the management of CRC. However, there are a number of significant issues. The lack of definition in the current edition of TNM is not acceptable as it leads to poor interobserver agreement. 57 True effects of the total number of TDs have not been determined, nor has this aspect been considered against the number of LNMs present. We do not know the optimal way to classify TDs after neoadjuvant treatment. Size of TDs seems to matter and further characterization is required. It is not clear how we should integrate these prognostic markers into the debate over when to use adjuvant therapy.
58
Despite all of these issues, TDs and their number should be fully included in TNM staging. Inclusion of TDs only in the absence of LNMs is not justified by the evidence. TDs and their actual number should be considered equal to the number of LNMs in making treatment decisions; therefore, the number of TDs should be added to the number of LNMs in nodal staging to derive a final N stage.
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